Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1

Molecular Cancer Therapeutics

Volumn 2, Issue 1, 2003, Pages 73-81

  Ma, Yihong ^a,b   Cress, W Douglas ^a,b   Haura, Eic B ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; E2F1 PROTEIN, HUMAN; E2F1 PROTEIN, MOUSE; FLAVONOID; FLAVOPIRIDOL; MCL1 PROTEIN; PIPERIDINE DERIVATIVE; PRIMER DNA; PROTEIN BCL 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TUMOR PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL STRAIN 3T3; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MOUSE; NUCLEOTIDE SEQUENCE;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DNA PRIMERS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; FLAVONOIDS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM PROTEINS; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0038754616     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Sherr, C. J. Cancer cell cycles. Science (Wash. DC), 274: 1672-1677, 1996.
2. Nevins, J. R. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ., 9: 585-593, 1998. (Pubitemid 28367248)
3. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
4. 1/S-regulatory genes [published erratum appears in Mol. Cell. Biol., 15: 5846-5847, 1995]. Mol. Cell. Biol., 15: 4215-4224, 1995.
5. 1 cyclin dependent kinase activity in the induction of S phase. Proc. Natl. Acad. Sci. USA, 96: 6626-6631, 1999.
6. Campbell, I., Magliocco, A., Moyana, T., Zheng, C., and Xiang, J. Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer Gene Ther. 7: 1270-1278, 2000.
7. Lee, J. H., Lee, C. T., Yoo, C. G., Hong, Y. K., Kim, C. M., Han, S. K., Shim, Y. S., Carbone, D. P., and Kim, Y. W. The inhibitory effect of adenovirus-mediated p16INK4a gene transfer on the proliferation of lung cancer cell line. Anticancer Res., 18: 3257-3261, 1998. (Pubitemid 28546443)
8. Jin, X., Nguyen, D., Zhang, W. W., Kyritsis, A. P., and Roth, J. A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res., 55: 3250-3253, 1995.
9. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. (Bethesda), 84: 1736-1740, 1992.
10. Worland, P. J., Kaur, G., Stetler-Stevenson, M., Sebers, S., Sartor, O., and Sausville, E. A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol., 46: 1831-1840, 1993. (Pubitemid 23349033)
11. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
12. Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig. New Drugs, 17: 313-320, 1999. (Pubitemid 30037961)
13. Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene, 19: 6600-6606, 2000. (Pubitemid 32197698)
14. Senderowicz, A. M., and Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (Bethesda), 92: 376-387, 2000. (Pubitemid 30154819)
15. Senderowicz, A. M. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. Cancer Chemother. Biol. Response Modif., 19: 165-188, 2001.
16. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., and Senderowicz, A. M. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4641, 1999. (Pubitemid 29428969)
17. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996. (Pubitemid 26116234)
18. Gray, N., Detivaud, L., Doerig, C., and Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem., 6: 859-875, 1999. (Pubitemid 29422199)
19. Kim, S. H., Schulze-Gahmen, U., Brandsen, J., and de Azevedo Junior, W. F. Structural basis for chemical inhibition of CDK2. Prog. Cell Cycle Res., 2: 137-145, 1996.
20. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 201: 589-595, 1994.
21. Meijer, L. Chemical inhibitors of cyclin-dependent kinases. Prog. Cell Cycle Res., 1: 351-363, 1995.
22. Sausville, E. A., Johnson, J., Alley, M., Zaharevitz, D., and Senderowicz, A. M. Inhibition of CDKs as a therapeutic modality. Ann. N Y Acad. Sci., 910: 207-221; discussion 221-2, 2000.
23. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., and Grever, M. R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood, 92: 3804-3816, 1998. (Pubitemid 28525207)
24. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Jr., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91: 2482-2490, 1998. (Pubitemid 28155524)
25. Decker, R. H., Dai, Y., and Grant, S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ., 8: 715-724, 2001. (Pubitemid 32685169)
26. Kitada, S., Zapata, J. M., Andreeff, M., and Reed, J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96: 393-397, 2000. (Pubitemid 30463354)
27. Konig, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., and Gabrilove, J. L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood, 90: 4307-4312, 1997. (Pubitemid 27508436)
28. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., Sausville, E. A., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998. (Pubitemid 28053367)
29. Pepper, C., Thomas, A., Hoy, T., Fegan, C., and Bentley, P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br. J. Haematol., 114: 70-77, 2001. (Pubitemid 32702635)
30. Senderowicz, A. M. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia (Baltimore), 15: 1-9, 2001. (Pubitemid 32124064)
31. Chen, Y. N., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., and Kaelin, W. G., Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA, 96: 4325-4329, 1999. (Pubitemid 29190335)
32. Leone, G., DeGregori, J., Sears, R., Jakoi, L., and Nevins, J. R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F [published erratum appears in Nature, 387: 932, 1997]. Nature (Lond.), 387: 422-426, 1997. (Pubitemid 27227209)
33. DeGregori, J., Leone, G., Miron, A., Jakoi, L., and Nevins, J. R. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA, 94: 7245-7250, 1997. (Pubitemid 27345300)
34. Field, S. J., Tsai, F. Y., Kuo, F., Zubiaga, A. M., Kaelin, W. G., Jr., Livingston, D. M., Orkin, S. H., and Greenberg, M. E. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell, 85: 549-561, 1996. (Pubitemid 26157193)
35. Johnson, D. G. The paradox of E2F1: oncogene and tumor suppressor gene. Mol. Carcinog., 27: 151-157, 2000. (Pubitemid 30149310)
36. Kowalik, T. F., DeGregori, J., Schwarz, J. K., and Nevins, J. R. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol., 69: 2491-500, 1995.
37. Kowalik, T. F., DeGregori, J., Leone, G., Jakoi, L., and Nevins, J. R. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ., 9: 113-118, 1998. (Pubitemid 128472551)
38. Pierce, A. M., Schneider-Broussard, R., Gimenez-Conti, I. B., Russell, J. L., Conti, C. J., and Johnson, D. G. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol. Cell. Biol., 19: 6408-6414, 1999. (Pubitemid 29399344)
39. Qin, X. Q., Livingston, D. M., Kaelin, W. G., Jr., and Adams. P. D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA, 91: 10918-22, 1994.
40. Tsai, K. Y., Hu, Y., Macleod, K. F., Crowley, D., Yamasaki, L., and Jacks, T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell., 2: 293-304, 1998. (Pubitemid 128379270)
41. Wu, X., and Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994. (Pubitemid 24139478)
42. Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E., and Dyson, N. J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell, 85: 537-548, 1996. (Pubitemid 26157192)
43. Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., and Vousden, K. H. p14ARF links the tumour suppressors RB and p53 [letter]. Nature (Lond.), 395: 124-125, 1998. (Pubitemid 28425642)
44. Chin, L., Pomerantz, J., and DePinho, R. A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem. Sci., 23: 291-296, 1998. (Pubitemid 28461894)
45. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., and DePinho, R. A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998. (Pubitemid 28155311)
46. Sherr, C. J., and Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev., 10: 94-99, 2000. (Pubitemid 30113711)
47. Tao, W., and Levine, A. J. p19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA, 96: 6937-6941, 1999. (Pubitemid 29274988)
48. Tao, W., and Levine, A. J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2- mediated degradation of p53. Proc. Natl. Acad. Sci. USA, 96: 3077-3080, 1999. (Pubitemid 29148846)
49. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell., 92: 725-734, 1998. (Pubitemid 28155312)
50. Croxton, R., Ma, Y., Song, L., Haura, E. B., and Cress, W. D. Direct repression of the Mcl-1 promoter by E2F1. Oncogene, 21: 1359-1369, 2002. (Pubitemid 34214501)
51. Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y., and Forrester, W. C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA, 99: 5515-5520, 2002. (Pubitemid 34411580)
52. Kaelin, W. G., Jr., Krek, W., Sellers, W. R., DeCaprio, J. A., Ajchenbaum, F., Fuchs, C. S., Chittenden, T., Li, Y., Farnham, P. J., Blanar, M. A., et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell, 70: 351-364, 1992.
53. Ma, Y., Croxton, R., Moorer, R. L., Jr., and Cress, W. D. Identification of novel E2F1-regulated genes by microarray. Arch. Biochem. Biophys. 399: 212-224, 2002. (Pubitemid 34848609)
54. Shapiro, G. I., Koestner, D. A., Matranga, C. B., and Rollins, B. J. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res., 5: 2925-2938, 1999. (Pubitemid 29493972)
55. Kataoka, M., Wiehle, S., Spitz, F., Schumacher, G., Roth, J. A., and Cristiano, R. J. Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene, 19: 1589-1595, 2000. (Pubitemid 30175681)
56. Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., and Kaelin, W. G., Jr. Role for the p53 homologue p73 in E2F-1-induced apoptosis, Nature. 407: 645-648, 2000.
57. Irwin, M. S., and Kaelin, W. G., Jr. Role of the newer p53 family proteins in malignancy. Apoptosis, 6: 17-29, 2001. (Pubitemid 32233952)
58. Irwin, M. S., and Kaelin, W. G. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ., 12: 337-349, 2001. (Pubitemid 32685635)
59. Moroni, M. C., Hickman, E. S., Denchi, E. L., Caprara, G., Colli, E., Cecconi, F., Muller, H., and Helin, K. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol., 3: 552-558, 2001. (Pubitemid 32536851)
60. Phillips, A. C., Bates, S., Ryan, K. M., Helin, K., and Vousden, K. H. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev., 11: 1853-1863, 1997. (Pubitemid 27315214)
61. Phillips, A. C., Ernst, M. K., Bates, S., Rice, N. R., and Vousden, K. H. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell., 4: 771-781, 1999.
62. Wolowiec, D., Benchaib, M., Pernas, P., Deviller, P., Souchier, C., Rimokh, R., Felman, P., Bryon, P. A., and Ffrench, M. Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue. Leukemia (Baltimore), 9: 1382-1388, 1995.
63. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996. (Pubitemid 26374418)
64. Matranga, C. B., and Shapiro, G. I. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S phase. Cancer Res., 62: 1707-1717, 2002. (Pubitemid 34408493)
65. Edamatsu, H., Gau, C. L., Nemoto, T., Guo, L., and Tamanoi, F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene, 19: 3059-3068, 2000. (Pubitemid 30438462)
66. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol., 2: 1-11, 2001.
67. Chao, S. H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., and Price, D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem., 275: 28345-8, 2000.
68. Ljungman, M., and Paulsen, M. T. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol., 60: 785-789, 2001. (Pubitemid 32900261)
69. Bresnahan, W. A., Boldogh, I., Chi, P., Thompson, E. A., and Albrecht, T. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology, 231: 239-247, 1997. (Pubitemid 27244190)
70. Leu, C. M., Chang, C., and Hu, C. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene, 19: 1665-1675, 2000. (Pubitemid 30200968)
71. Puthier, D., Derenne, S., Barille, S., Moreau, P., Harousseau, J. L., Bataille, R., and Amiot, M. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br. J. Haematol., 107: 392-395, 1999. (Pubitemid 29530231)
72. Epling-Burnette, P. K., Zhong, B., Bai, F., Jiang, K., Bailey, R. D., Garcia, R., Jove, R., Djeu, J. Y., Loughran, T. P., Jr., and Wei, S. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J. Immunol., 166: 7486-7495, 2001. (Pubitemid 32525627)
73. Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R., and Loughran, T. P., Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Investig., 107: 351-362, 2001.
74. Araki, T., Hayashi, M., Watanabe, N., Kanuka, H., Yoshino, J., Miura, M., and Saruta, T. Down-regulation of Mcl-1 by inhibition of the PI3-K/Akt pathway is required for cell shrinkage-dependent cell death. Biochem. Biophys. Res. Commun., 290: 1275-1281, 2002. (Pubitemid 34694443)
75. Kuo, M. L., Chuang, S. E., Lin, M. T., and Yang, S. Y. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene, 20: 677-685, 2001.
76. Liu, H., Perlman, H., Pagliari, L. J., and Pope, R. M. Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-κB, Bad, or caspase activation. J. Exp. Med., 194: 113-126, 2001.
77. Wang, J. M., Chao, J. R., Chen, W., Kuo, M. L., Yen, J. J., and Yang-Yen, H. F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol., 19: 6195-206, 1999. (Pubitemid 29399324)
78. Smith, V., Raynaud, F., Workman, P., and Kelland, L. R. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Mol. Pharmacol., 60: 885-893, 2001. (Pubitemid 33027422)